ReviewFrontiers in cellular and infection microbiology2013
Burkholderia vaccines: are we moving forward?
Review in Frontiers in cellular and infection microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 73 citations in OpenAlex.
- Secretion systems shaping host-pathogen interactions in Burkholderia species.Applied microbiology and biotechnology · 2026Review
- Glanders: Past, Present and Future of a Neglected Zoonosis as a Threat in Veterinary and Human Health.Veterinary medicine and science · 2026Review
- Glanders: An ancient and emergent disease with no vaccine or treatment on site.PLoS neglected tropical diseases · 2025Review
- Tracking the footsteps of Burkholderia mallei: determination of the molecular differences and potential resistance genes.Turkish journal of medical sciences · 2024Article
- Nanomedicine: New Frontiers in Fighting Microbial Infections.Nanomaterials (Basel, Switzerland) · 2023Review
- Designing a novel chimeric multi-epitope vaccine againstFrontiers in medicine · 2022Article
- One Health surveillance approaches for melioidosis and glanders: The Malaysian perspective.Frontiers in veterinary science · 2022Review
- Immunization and Immunotherapy Approaches againstVaccines · 2021Review
- Hijacking of the Host's Immune Surveillance Radars byFrontiers in immunology · 2021Review
- A novel gonorrhea vaccine composed of MetQ lipoprotein formulated with CpG shortens experimental murine infection.Vaccine · 2020Article
- Evaluation of Burkholderia mallei ΔtonB Δhcp1 (CLH001) as a live attenuated vaccine in murine models of glanders and melioidosis.PLoS neglected tropical diseases · 2019Article
- Burkholderia pseudomallei ΔmSphere · 2019Article
- Antibodies Are Major Drivers of Protection against Lethal Aerosol Infection with Highly PathogenicmSphere · 2019Article
- Differential effects of Th17 cytokines during the response of neutrophils toCentral-European journal of immunology · 2019Article
- Relapse of chronic melioidosis in a paediatric cystic fibrosis patient: first case report from Malaysia.BMC infectious diseases · 2018Article
- Postgenomic Approaches and Bioinformatics Tools to Advance the Development of Vaccines against Bacteria of theVaccines · 2018Review
- Use of Immunohistochemistry to Demonstrate In Vivo Expression of the Burkholderia mallei Virulence Factor BpaB During Experimental Glanders.Veterinary pathology · 2018Article
- Immune Control ofFrontiers in immunology · 2018Article
- Structural characterisation of the capsular polysaccharide expressed by Burkholderia thailandensis strain E555:: wbiI (pKnock-KmR) and assessment of the significance of the 2-O-acetyl group in immune protection.Carbohydrate research · 2017Article
- DNA vaccination resurfaces in the struggle against melioidosis.Virulence · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genus Burkholderia consists of diverse species which includes both "friends" and "foes." Some of the "friendly" Burkholderia spp. are extensively used in the biotechnological and agricultural industry for bioremediation and biocontrol. However, several members of the genus including B. pseudomallei, B. mallei, and B. cepacia, are known to cause fatal disease in both humans and animals. B. pseudomallei and B. mallei are the causative agents of melioidosis and glanders, respectively, while B. cepacia infection is lethal to cystic fibrosis (CF) patients. Due to the high rate of infectivity and intrinsic resistance to many commonly used antibiotics, together with high mortality rate, B. mallei and B. pseudomallei are considered to be potential biological warfare agents. Treatments of the infections caused by these bacteria are often unsuccessful with frequent relapse of the infection. Thus, we are at a crucial stage of the need for Burkholderia vaccines. Although the search for a prophylactic therapy candidate continues, to date development of vaccines has not advanced beyond research to human clinical trials. In this article, we review the current research on development of safe vaccines with high efficacy against B. pseudomallei, B. mallei, and B. cepacia. It can be concluded that further research will enable elucidation of the potential benefits and risks of Burkholderia vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.